Home News New results confirmation for Arcede Pharma

New results confirmation for Arcede Pharma

Arcede results

New results confirmation for Arcede Pharma

10 May, 2024

Preclinical studies at the Università degli Studi di Roma Tor Vergata confirm that the drug candidate RCD405 has both airway dilation and anti-inflammatory effects. Thus, another piece is added to the development puzzle for the Lund-based company, which is aiming for the ever-growing COPD and asthma markets.

RCD405’s dual mechanism of action distinguishes the candidate from currently available drugs for chronic obstructive pulmonary disease (COPD). In doing so, Arcede Pharma hopes to provide a more effective treatment option to the millions of people suffering from COPD and other respiratory diseases.

Last year, Arcede Pharma completed the toxicology programme with RCD405, which means that the regulatory prerequisites for initiating clinical studies are now in place. Acting CEO Erik Magnusson is currently working with the Board of Directors on a strategic development plan and to resolve the financing of this next step.

Mapping confirms previous preclinical results

In the preclinical work, RCD405’s mechanisms of action have also been mapped to gain a better understanding of its properties. During the autumn, the results of collaborations with research groups at both Lund University and Karolinska Institutet were presented, where the candidate was found to have both airway relaxant and anti-inflammatory effects.

Arcede has also worked together with the medical technology company Iconovo on the candidate’s pharmacology, with the aim of being able to make dose predictions for the use of Iconovo’s inhalation platforms. The idea is that RCD405 will be administered via inhalation.

New results guide the work forward

Further results from preclinical studies carried out with Università degli Studi di Roma Tor Vergata are now presented, that confirm the results from Lund and Karolinska. RCD405 provides concentration-dependent relaxation of human bronchial tissue. According to the company, “the efficacy and potency profile against both cholinergic and histaminergic sensitivity suggests promising prospects for future clinical trials in asthma and COPD.”

Erik Magnusson writes in a press release that the results demonstrate the drug candidate’s translational effect and provide valuable insights to guide future preclinical and clinical investigations in the field of respiratory medicine.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev